{
    "symbol": "EDIT",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-02 10:50:29",
    "content": " Please proceed with your question. Please proceed with your question. Thanks for taking the question. Thanks for taking the question. Thanks for taking the question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Thanks for taking the question. With regard to positioning, we believe that the space, because it's new and because of the very high unmet need tempered by what we would have just said over the next couple of years might be some hesitancy in uptake, and very importantly the evolution of the payer landscape that we will actually be in a very good position with the timing and progression and progress we're making with the 301 program that the majority of the prevalent patients will actually still be awaiting therapy at the time of our launch."
}